Aeglea BioTherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aeglea BioTherapeutics generated cash of -$80,144,000, which is less than the previous year. Cash used in financing activities reached the amount of $42,678,000 last year. Net change in cash is therefore $19,436,000.
Cash Flow
| 2014 | -7.33M | -221K | 5.57M |
|---|---|---|---|
| 2015 | -10.98M | -4.01M | 41.67M |
| 2016 | -18.84M | -12.07M | 49.37M |
| 2017 | -24.61M | -22.52M | 12.21M |
| 2018 | -32.19M | -15.23M | 57.06M |
| 2019 | -65.69M | -1.73M | 65.72M |
| 2020 | -75.77M | -7.60M | 154.51M |
| 2021 | -53.71M | -22.61M | 1.39M |
| 2022 | -80.14M | 57.00M | 42.67M |
AGLE Cash Flow Statement (2014 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 16.98M | 91.93M | 20.75M | 22.46M | 12.81M | 47.74M | 29.29M | 2.61M | 4.59M |
Operating activities | |||||||||
Net income | -83.81M | -65.80M | -80.89M | -78.25M | -44.34M | -27.23M | -21.69M | -11.29M | -10.34M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 1.56M | 1.57M | 996K | 418K | 293K | 249K | 132K | 89K | 19K |
Stock-based compensation expense | 7.11M | 8.03M | 6.25M | 4.87M | 4.28M | 2.49M | 1.22M | 767K | 147K |
| Deferred income tax benefit | 7.11M | 8.03M | 6.25M | 4.87M | 4.28M | 2.49M | 1.22M | 767K | 147K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 3.07M | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 3.90M | 0 | 0 | 0 | 0 |
Accounts payable | -2.64M | 1.06M | -544K | 2.58M | 239K | 164K | -8K | -169K | 102K |
Cash generated by operating activities | -80.14M | -53.71M | -75.77M | -65.69M | -32.19M | -24.61M | -18.84M | -10.98M | -7.33M |
Investing activities | |||||||||
Purchases Of Investments | -39.5M | -133.07M | -129M | -91.92M | -62.17M | -64.11M | -20.39M | -3.76M | 0 |
Investments In Property Plant And Equipment | -38K | -573K | -4.28M | -1.49M | -422K | -619K | -212K | -208K | -181K |
Acquisitions Net | 428K | -344K | -286K | 504K | 907K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 57.00M | -22.61M | -7.60M | -1.73M | -15.23M | -22.52M | -12.07M | -4.01M | -221K |
Financing activities | |||||||||
Common Stock Issued | 42.87M | 0 | 153.71M | 64.29M | 54.04M | 11.38M | 49.29M | 43.70M | 5.57M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -510K | -20K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 42.67M | 1.39M | 154.51M | 65.72M | 57.06M | 12.21M | 49.37M | 41.67M | 5.57M |
Net Change In Cash | 19.43M | -74.95M | 71.18M | -1.70M | 9.64M | -34.93M | 18.45M | 26.67M | -1.98M |
Cash at end of period | 36.41M | 16.98M | 91.93M | 20.75M | 22.46M | 12.81M | 47.74M | 29.29M | 2.61M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |